Copenhagen Mesenteric Stent Study - A Randomized Trial of Stent Versus Covered Stent Treatment for Chronic Mesenteric Ischemia

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorRigshospitalet, Denmark

About this trial

Chronic mesenteric ischemia (CMI) is often caused by narrowings in the arteries providing blood to the intestines. Endovascular stent placement is considered the preferred treatment for this condition. Guidelines increasingly support the use of so called covered stents (CS) in stead of bare stents (BMS) for this use but the level of evidence for this is limited. Using CS incur additional costs for healthcare short-term but may prevent recurrence of narrowing and symptoms postoperatively benefitting patients and healthcare.

Study Objective:

To evaluate the outcomes after stenting of mesenteric arteries using BMS or CS.

Study Outcome:

Primary stent patency 1 year after placement

The trial will also evaluate complications, how often stents need to be reoperated, Quality of Life (QoL) and reasons for subjects death

Method:

This is a so called prospective, randomized controlled trial comparing CS vs. BMS. This means that one patients have agrred to treatment they will be randomly selected for treatment with either CS or BMS . The stent metal structure is identical in the two implants and the only difference is the graft covering, making this study unique.

The study will also collect blood samples for a biobank that will be used to study markers of disease and how these effect treatment outcomes.

All patients referred to the Department of Vascular Surgery due to CMI are considered for inclusion if they havechronic symptoms consistent with CMI, significant stenosis or occlusion of the superior mesenteric artery and are \> 18 years Subjects not able to provide informed consent or who have non atherosclerotic cause of CMI, signs of acute loss of blood flow to the intestines cannot participate. Previous stent treatment in the superior mesenteric artery, pregnancy, allergies to contrast or stent materials are also reasons for not being included in this trial.

Side effects, risks and disadvantages for participants The risk for procedure-related complications is less than 5% and similar in both study groups. Most short-term complications are related to vascular access sites and consist of local bleeding and thrombosis. Other potential complications include impaired renal function due to contrast use, contrast allergy, arterial dissection and death.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Patients with symptomatic CMI of atherosclerotic or atherothrombotic etiology

Intended endovascular treatment

Symptoms consistent with CMI (pain, weight loss, diarrhea)

Significant ostial stenosis (>50%) of the superior mesenteric artery on CTA

Disqualifiers

No informed consent

Non atherosclerotic cause of MI

Acute mesenteric ischemia (AMI)

Signs of acute bowel ischemia, peritonitis, laparotomy, sepsis

Trial design

Design model

Parallel

Treatments tested in this trial

  • BMS vs. CS

    Device

    Patients will be randomized to treatment with either BeSmooth (BMS, Bentley Innomed GmBh) or BeGraft (CS, Bentley Innomed Gmbh)

Treatment groups

98 Participants
are divided into 2 treatment groups
Group A: Bare Metal StentActive comparator 1 intervention
Group B: Covered StentActive comparator 1 intervention

Trial outcomes

Primary outcomes

1

Number of patients with open stents after 12 months

No evidence of occlusion, thrombosis or in-stent restenosis more than 30 percent

Time frame
12 months

Secondary outcomes

1

Survival

reintervention free and overall survival

Time frame
5 years
2

Quality of life accoring to SF 36 variables

SF 36

Time frame
5 years

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Rigshospitalet, Denmark

Lead sponsor

University of Copenhagen

Collaborator